Tilray’s aggressive expansion in Germany’s medical cannabis market, paired with a fiscal 2025 net revenue of $821 million and improved margins, showcases a push for global prominence. The cannabis sector’s projected $444 billion value by 2030, recent optimism, and Tilray’s latest product launch spotlight the company’s strategic positioning.

With a market capitalization of $1.78 billion, Tilray trades at a discount compared to its cannabis peers. Fiscal year 2025 earnings reflect steady growth, with a net revenue increase to $821 million. Despite a net loss of $2.18 billion, adjusted net income rose 45% to $9 million, and adjusted EBITDA stood at $55 million.

Tilray’s recent expansion in Germany aligns with growing optimism, spurred by President Trump’s endorsement of medical cannabis potential. The company’s launch of five new cannabis products in Germany, crafted to meet EU-GMP standards, underscores its commitment to quality and consistency in the market.

Analysts anticipate Tilray’s upcoming earnings release on Oct. 9, with a focus on adjusted earnings per share and guidance for fiscal 2026. Management projects adjusted EBITDA between $62 million and $72 million for fiscal 2026, signaling potential growth from operational improvements.

While analysts offer a moderately bullish outlook on Tilray, with an average price target of $1.21, they expect limited near-term upside. Patient investors may view Tilray as a hold, awaiting clearer profits and regulatory developments. The stock’s performance hinges on successful execution of its business strategy and sustained earnings growth.

Read more at Yahoo Finance: As Tilray Expands Its Medical Cannabis Business, Should You Buy, Sell, or Hold TLRY Stock?